EVALUATION OF HOSPITAL AND COMMUNITY-ACQUIRED INFECTION RATES FOR KLEBSIELLA PNEUMONIAE THAT PRODUCES CARBAPENEMS

Abstract

Background: The most frequent pathogens in the Enterobacteriaceae family that cause fatal infections include Klebsiella
pneumoniae, for which carbapenems are used as a last option to treat drug-resistant Gram-negative bacterial infections.
The growing incidence of carbapenem-resistant Klebsiella species has been blamed for a number of treatment failures in
recent years.
Aim: The purpose is to determine how common hospital and community-acquired infections are caused by Klebsiella
pneumoniae that produces carbapenems.
Methods: During the designated study period, samples submitted to the Institute's Microbiology Laboratory were
evaluated for this investigation. Klebsiella pneumoniae was isolated from a variety of clinical samples among processed
samples, and the isolates were categorized based on clinical history of hospital-acquired and community-acquired
illnesses. The Kirby-Bauer disc diffusion method was used for antibiotic susceptibility testing, or AST. The Modified
Carbapenemase Inactivation Test (m-CIM) was used to identify crabapenamase manufacturers.